New combo therapy shows promise for Hard-to-Treat breast cancer
NCT ID NCT05064085
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This early-phase study tested a combination of two drugs—capecitabine (a chemotherapy pill) and cemiplimab (an immunotherapy)—in 13 people with hormone receptor-positive breast cancer that had spread. The main goal was to find the safest dose and see if the combo could shrink tumors. While not a cure, the approach aims to better control the disease in patients who have limited options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Virtual therapy may ease breast cancer treatment side effects
- A gentle jog might be the key to better sleep for breast cancer survivors
- Ovarian suppression plus tamoxifen: a Long-Term bet against breast cancer recurrence
- Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer
- New drug cocktail aims to outsmart resistant breast cancer
- Can a smartphone app help latina breast cancer patients beat the odds?